Literature DB >> 18813125

Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases.

Mahul B Amin1, Gladell P Paner, Isabel Alvarado-Cabrero, Andrew N Young, Hans J Stricker, Robert H Lyles, Holger Moch.   

Abstract

The aggregate literature suggests that chromophobe renal cell carcinoma (RCC) is biologically a tumor of low malignant potential with reported 5-year and 10-year survival rates of 78% to 100% and 80% to 90%, respectively. The conventional prognostic parameters that determine the outcome of the tumors that progress remain to be fully characterized. Clinicopathologic features of 145 cases were correlated with outcome. The mean age of the patients was 59 years (range, 27 to 82) and the male to female ratio was 1.1:1. Most tumors were well circumscribed and averaged 8.0 cm (range, 1.0 to 30.0 cm); multifocality and bilaterality were present in 8% and 3% of patients. Sixty (41%) were eosinophilic variant (greater than 80% eosinophilic cells), 18 (12%) were classic type (greater than 80% pale cells), and 67 (46%) were mixed (containing variable admixture of pale and eosinophilic cells). A subset of eosinophilic chromophobe RCC contained or had areas similar to renal oncocytomas. These tumors tended to be more commonly bilateral (11%) and multifocal (22%) and were not associated with necrosis or sarcomatoid change. Sarcomatoid change was present in 12/145 (8%) tumors. By histologic grade, 1%, 19%, 74%, 6% were Fuhrman nuclear grade 1, 2, 3, and 4. Nineteen percent, 21%, 28%, 13%, 4%, 1%, and 3% were pT (2002) stage pT1a, pT1b, pT2, pT3a, pT3b, pT3c, and pT4 tumors. Two percent tumors were pN1 at presentation and 2.8% tumors were M1 at presentation. Follow-up (1 to 182 mo, mean 48 mo, median 37 mo) was available in 123 cases. Disease progression (local recurrence 4, metastasis 15, and/or death 10) was seen in 20 patients. In univariable analysis, tumor size (P=0.025), pT stage (P<0.001), broad alveolar architecture (P=0.012), Fuhrman nuclear grade (P<0.001), microscopic tumor necrosis (P=0.001), vascular invasion (P=0.020), and sarcomatoid change (P< or =0.001) were associated with progression. A multivariable Cox regression model revealed sarcomatoid change (P=0.013, estimated relative hazard 4.7), microscopic necrosis (P=0.020, relative hazard=3.5), and pT stage (P=0.025, relative hazard 3.4) as independent predictors of aggressive chromophobe RCC. Although the large majority of chromophobe RCCs have a favorable prognosis, a distinct subset of patients progress. The pT stage of tumor, tumor necrosis, and sarcomatoid change all predict aggressive phenotype of chromophobe RCC. The adverse presence of these features in a nephrectomy specimen with chromophobe RCC warrants active surveillance, and these patients may be candidates for adjuvant therapies as they become available.

Entities:  

Mesh:

Year:  2008        PMID: 18813125     DOI: 10.1097/PAS.0b013e3181831e68

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  70 in total

1.  A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma.

Authors:  Nizar M Tannir; Elizabeth Plimack; Chaan Ng; Pheroze Tamboli; Nebiyou B Bekele; Lianchun Xiao; Lisa Smith; Zita Lim; Lance Pagliaro; John Araujo; Ana Aparicio; Surena Matin; Christopher G Wood; Eric Jonasch
Journal:  Eur Urol       Date:  2012-06-27       Impact factor: 20.096

2.  The somatic genomic landscape of chromophobe renal cell carcinoma.

Authors:  Caleb F Davis; Christopher J Ricketts; Min Wang; Lixing Yang; Andrew D Cherniack; Hui Shen; Christian Buhay; Hyojin Kang; Sang Cheol Kim; Catherine C Fahey; Kathryn E Hacker; Gyan Bhanot; Dmitry A Gordenin; Andy Chu; Preethi H Gunaratne; Michael Biehl; Sahil Seth; Benny A Kaipparettu; Christopher A Bristow; Lawrence A Donehower; Eric M Wallen; Angela B Smith; Satish K Tickoo; Pheroze Tamboli; Victor Reuter; Laura S Schmidt; James J Hsieh; Toni K Choueiri; A Ari Hakimi; Lynda Chin; Matthew Meyerson; Raju Kucherlapati; Woong-Yang Park; A Gordon Robertson; Peter W Laird; Elizabeth P Henske; David J Kwiatkowski; Peter J Park; Margaret Morgan; Brian Shuch; Donna Muzny; David A Wheeler; W Marston Linehan; Richard A Gibbs; W Kimryn Rathmell; Chad J Creighton
Journal:  Cancer Cell       Date:  2014-08-21       Impact factor: 31.743

3.  Morphological, immunohistochemical, and chromosomal analysis of multicystic chromophobe renal cell carcinoma, an architecturally unusual challenging variant.

Authors:  Maria Pané Foix; Ana Dunatov; Petr Martinek; Enric Condom Mundó; Saul Suster; Maris Sperga; Jose I Lopez; Monika Ulamec; Stela Bulimbasic; Delia Perez Montiel; Reza Alaghehbandan; Kvetoslava Peckova; Krystina Pivovarcikova; Daum Ondrej; Pavla Rotterova; Faruk Skenderi; Kristyna Prochazkova; Martin Dusek; Milan Hora; Michal Michal; Ondrej Hes
Journal:  Virchows Arch       Date:  2016-09-15       Impact factor: 4.064

4.  [The WHO/ISUP grading system for renal carcinoma].

Authors:  H Moch
Journal:  Pathologe       Date:  2016-07       Impact factor: 1.011

5.  Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276).

Authors:  Youfeng Yang; Cathy D Vocke; Christopher J Ricketts; Darmood Wei; Hesed M Padilla-Nash; Martin Lang; Carole Sourbier; J Keith Killian; Shawna L Boyle; Robert Worrell; Paul S Meltzer; Thomas Ried; Maria J Merino; Adam R Metwalli; W Marston Linehan
Journal:  Genes Chromosomes Cancer       Date:  2017-07-24       Impact factor: 5.006

Review 6.  Diagnostic approach to eosinophilic renal neoplasms.

Authors:  Oleksandr N Kryvenko; Merce Jorda; Pedram Argani; Jonathan I Epstein
Journal:  Arch Pathol Lab Med       Date:  2014-11       Impact factor: 5.534

7.  Identification and Validation of Radiographic Enhancement for Reliable Differentiation of CD117(+) Benign Renal Oncocytoma and Chromophobe Renal Cell Carcinoma.

Authors:  Jay Amin; Bo Xu; Shervin Badkhshan; Terrance T Creighton; Daniel Abbotoy; Christine Murekeyisoni; Kristopher M Attwood; Thomas Schwaab; Craig Hendler; Michael Petroziello; Charles L Roche; Eric C Kauffman
Journal:  Clin Cancer Res       Date:  2018-05-11       Impact factor: 12.531

8.  Prognostic significance of grading in lung adenocarcinoma.

Authors:  Justine A Barletta; Beow Y Yeap; Lucian R Chirieac
Journal:  Cancer       Date:  2010-02-01       Impact factor: 6.860

Review 9.  Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact.

Authors:  Brandon J Manley; Abraham Ari Hakimi
Journal:  Curr Opin Urol       Date:  2016-09       Impact factor: 2.309

Review 10.  Chromophobe renal cell cancer--review of the literature and potential methods of treating metastatic disease.

Authors:  Rafał Stec; Bartłomiej Grala; Michał Maczewski; Lubomir Bodnar; Cezary Szczylik
Journal:  J Exp Clin Cancer Res       Date:  2009-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.